Health Condition 1: G430- Migraine without aura
Conditions
Interventions
Intervention1: Magnesium oxide: This is a nutraceutical available in tablet form.
Dose-400mg
Frequency-once a day (Morning)
Duration of treatment-3 months
Control Intervention1: Flunarizine: This is
Sponsors
NIL
Eligibility
Inclusion criteria
Inclusion criteria: Patients diagnosed with migraine without aura according to the diagnostic criteria specified by ICHD-3 (International classification of headache disorders) Patients having no abnormal findings on systemic and neurological examination. Having more than 3 migraine attacks per month. Not having taken any prophylactic medicines for migraine in the last 4 months Patients who provide consent
Exclusion criteria
Exclusion criteria: Suffering from heart, liver, and renal diseases. A blood pressure over 180/95 mm of Hg, pregnancy or lactation. Usage of alcohol and drug abuse. Patients not willing to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare the efficacy and safety of flunarizine and magnesium oxide in reducing migraine frequency and severity.Timepoint: Follow up is scheduled at 2 weeks, 4 weeks and 12 weeks. | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess the change in migraine related disabilityTimepoint: 12 weeks (Disability assessed at baseline that is 0th week);To assess the use of analgesics during migraine attacksTimepoint: 12 weeks (Use of analgesics will be assessed at follow up during 2 weeks, 4 weeks and 12 weeks) | — |
Countries
India
Contacts
Public ContactDrSmitha Chandra B C
PESU Institute of medical sciences and research
Outcome results
None listed